3
ALL1
Adalvo1
Akums Drugs & Pharmaceuticals Ltd1
CiplaYear
3
ALL2
20231
2022DEALS // DEV.
3
ALL3
DevelopmentsCountry
3
ALL2
INDIA1
U.S.A3
ALL1
Adamed Pharma2
InapplicableTherapeutic Area
3
ALL1
Psychiatry/Psychology2
UrologyStudy Phase
3
ALL3
Approved FDFDeal Type
3
ALL3
InapplicableProduct Type
3
ALL3
Other Small MoleculeDosage Form
3
ALL2
Oral Capsule1
Oral Tablet, Modified ReleaseLead Product
3
ALL1
Solifenacin Succinate2
TamsulosinTarget
3
ALL1
5-hydroxytryptamine receptor 1A1
Adrenergic alpha-A1 receptor1
M2 receptorLead Product(s) : Tamsulosin,Tadalafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Introduces Tamsulosin + Tadalafil Capsule — to the Indian Market
Details : DCGI has approved Tamsulosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil, a fixed dose combination within a hard gelatin capsule for the treatment of erectile dysfunction & benign prostatic hyperplasia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : Tamsulosin,Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Adamed Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe
Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Product Name : Vesomni-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Adamed Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tamsulosin,Solifenacin Succinate
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDSCO Panel Gives Nod for FDC Tamsulosin + Solifenacin
Details : Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Tamsulosin,Solifenacin Succinate
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable